阿尔法陶医疗
DRTS
12.29
-0.87
-6.61%
阿尔法陶医疗
US · DRTS
#3046 按市值排名
上市于 1970
12.29
-0.87
-6.61%
实时 - 追踪5344个代码 - 心跳于201秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 24.65% -0.05pp
- 机构数量
- 80 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Public Company15.85%
Individual/Insider14.91%
Mutual Fund6.47%
Hedge Fund1.87%
Private Company0.28%
Family Office/Trust0.17%
Other60.45%
主要股东 截至 2026-05-12
Oramed Pharmaceuticals Inc.
15.67% · 14.47M 股
Uzi Sofer
12.47% · 11.52M 股
Michael Avruch
1.64% · 1.52M 股
Gem Investment Advisors, LLC
1.55% · 1.43M 股
HighTower Advisors, LLC
0.95% · 874.99K 股
Boothbay Fund Management, LLC
0.84% · 773.48K 股
Aquamarine Financial (Cayman) Ltd
0.78% · 721.50K 股
Pier Capital, LLC
0.75% · 691.94K 股
UBS Asset Management
0.70% · 642.26K 股
Yona Keisari
0.55% · 503.49K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪41份申报 · 0次买入 · 16次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Michael Avruch | Director | 1.64% |
| Yona Keisari | Chief Scientific Officer & Member of Scientific Advisory board | 0.55% |
| Raphi Levy | Chief Financial Officer | 0.10% |
| David Milch | Independent Director | 0.10% |
| Samuel Blumenfeld | Independent Director | 0.05% |
| Ruth Alon | Independent Director | -- |
| Alan Adler | Independent Director | -- |
| Nadav Kidron | Director | -- |
| Maya Racine-Netser | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-20 | Raphi Levy | Chief Financial Officer | Derivative Exercise and Sale | -2,871 | $2.98–15.00 |
| 2026-08-10 | Raphi Levy | Chief Financial Officer | Derivative Exercise and Sale | -17,730 | $2.98–14.00 |
| 2026-07-05 | Raphi Levy | Chief Financial Officer | Derivative Exercise and Sale | -2,270 | $2.98–14.00 |
| 2026-07-01 | Raphi Levy | Chief Financial Officer | Derivative Exercise and Sale | -17,873 | $2.98–13.00 |
| 2026-06-30 | Raphi Levy | Chief Financial Officer | Derivative Exercise and Sale | -2,127 | $2.98–13.02 |
| 2026-06-29 | Raphi Levy | Chief Financial Officer | Open Market Disposition | -20,000 | $12.00 |
| 2026-06-24 | Raphi Levy | Chief Financial Officer | Open Market Disposition | -20,000 | $11.00 |
| 2026-06-22 | Raphi Levy | Chief Financial Officer | Open Market Disposition | -17,500 | $9.47–10.00 |
| 2026-06-02 | Raphi Levy | Chief Financial Officer | Open Market Disposition | -32,500 | $10.76–10.90 |
| 2026-03-17 | Ruth Alon | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Alan Adler | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | David Milch | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Samuel Blumenfeld | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Nadav Kidron | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Maya Racine-Netser | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Raphi Levy | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Michael Avruch | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-24 | Raphi Levy | Chief Financial Officer | Intent to Sell (Form 144) | -10,000 | $7.40 |
| 2026-01-12 | Raphi Levy | Chief Financial Officer | Intent to Sell (Form 144) | -15,000 | $7.09 |
| 2026-01-08 | Raphi Levy | Chief Financial Officer | Intent to Sell (Form 144) | -25,000 | $6.41 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿尔法陶医疗 讨论区 0 条评论